Building A Better Biomarker: PD-L1 Expression Under Spotlight At ASCO
With new data showing correlation to response, use of PD-L1 expression as a biomarker for PD-1/L1 inhibitors was a frequent topic at ASCO. Its limitations point to need for better markers to guide immunotherapy use.
You may also be interested in...
Survey of recent literature shows breadth and quality of early research activity aimed at developing biomarkers to predict response to PD-1 and CTLA-4 checkpoint inhibitors.
Specialty pharma Neuraxpharm is taking on 38 mature brands from Sanofi, in CNS, pain and vascular diseases. Lilly is working with Triastek on 3D printing technology for targeted release of drugs in specific regions of the gastrointestinal tract.
Biogen caught a lucky break in getting the first FDA approval for a potentially disease-modifying Alzheimer’s therapy, but doubt over clinical benefit and commercial missteps have left Biogen in a precarious position a year later.